Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Li-Peng Hu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5941-3825; OpenAlex author ID A5016735063, A5124167250. Sources: OpenAlex.

Their work

Papers
28 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
70
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: 3 papers · 2021: 6 papers · 2022: 4 papers · 2023: 2 papers · 2024: 3 papers · 2025: 3 papers · 2026: 2 papers

Papers 28

  1. A peritumoral microenvironment engaged by Reg-EXTL3 axis fosters nerve-cancer interactions in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.neuron.2026.03.039↗
  2. A cholesterol-dependent LRRC8A-caveolin-1 axis sustains KRAS/EGFR signaling, ribosome biogenesis and growth in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-026-03864-z↗
  3. Vitamin D Binding Protein, a Ligand of Integrin beta 1, Motivates Both Tumor Cells and Schwann Cells to Promote Perineural Invasion in Pancreatic Ductal Adenoc… Co-author DOI 10.1002/advs.202511726↗
  4. ENO1 promotes PDAC progression by inhibiting CD8+ T cell infiltration through upregulating PD-L1 expression via HIF-1α signaling. Co-author DOI 10.1016/j.tranon.2024.102261↗
  5. OASL promotes immune evasion in pancreatic ductal adenocarcinoma by enhancing autolysosome-mediated degradation of MHC-I. Co-author DOI 10.7150/thno.103494↗
  6. Corrigendum to "Aberrant upregulation of KLK10 promotes metastasis via enhancement of EMT and FAK/SRC/ERK axis in PDAC." [Biochem. Biophys. Res. Commun. 499 (3… Co-author DOI 10.1016/j.bbrc.2023.149426↗
  7. AGFG1 increases cholesterol biosynthesis by disrupting intracellular cholesterol homeostasis to promote PDAC progression. Co-author DOI 10.1016/j.canlet.2024.217130↗
  8. A CLIC1 network coordinates matrix stiffness and the Warburg effect to promote tumor growth in pancreatic cancer. Co-author DOI 10.1016/j.celrep.2024.114633↗
  9. METTL3 suppresses pancreatic ductal adenocarcinoma progression through activating endogenous dsRNA-induced anti-tumor immunity. Co-author DOI 10.1007/s13402-023-00829-2↗
  10. Coadaptation fostered by the SLIT2-ROBO1 axis facilitates liver metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-023-36521-0↗
  11. Modeling of cancer-related body-wide effects identifies LTB4 as a diagnostic biomarker for pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2022.104050↗
  12. A low amino acid environment promotes cell macropinocytosis through the YY1-FGD6 axis in Ras-mutant pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-021-02159-9↗
  13. Increased SPON1 promotes pancreatic ductal adenocarcinoma progression by enhancing IL-6 trans-signalling. Co-author DOI 10.1111/cpr.13237↗
  14. GJB3 promotes pancreatic cancer liver metastasis by enhancing the polarization and survival of neutrophil. Last author DOI 10.3389/fimmu.2022.983116↗
  15. Single-cell RNA sequencing reveals that targeting HSP90 suppresses PDAC progression by restraining mitochondrial bioenergetics. Co-author DOI 10.1038/s41389-021-00311-4↗
  16. Reciprocal regulation of LOXL2 and HIF1α drives the Warburg effect to support pancreatic cancer aggressiveness. Co-author DOI 10.1038/s41419-021-04391-3↗
  17. Identification of a subset of immunosuppressive P2RX1-negative neutrophils in pancreatic cancer liver metastasis. First author DOI 10.1038/s41467-020-20447-y↗
  18. Increased Nuclear Transporter KPNA2 Contributes to Tumor Immune Evasion by Enhancing PD-L1 Expression in PDAC. Co-author DOI 10.1155/2021/6694392↗
  19. Deciphering the genomic and lncRNA landscapes of aerobic glycolysis identifies potential therapeutic targets in pancreatic cancer. Co-author DOI 10.7150/ijbs.49243↗
  20. The short isoform of PRLR suppresses the pentose phosphate pathway and nucleotide synthesis through the NEK9-Hippo axis in pancreatic cancer. Co-author DOI 10.7150/thno.51712↗
  21. TRIM59 predicts poor prognosis and promotes pancreatic cancer progression via the PI3K/AKT/mTOR-glycolysis signaling axis. Co-author DOI 10.1002/jcb.29433↗
  22. BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41556-019-0455-6↗
  23. Perineural Invasion Reprograms the Immune Microenvironment through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-19-2689↗
  24. GABRP regulates chemokine signalling, macrophage recruitment and tumour progression in pancreatic cancer through tuning KCNN4-mediated Ca2+ signalling in a GAB… Co-author DOI 10.1136/gutjnl-2018-317479↗
  25. Targeting Purinergic Receptor P2Y2 Prevents the Growth of Pancreatic Ductal Adenocarcinoma by Inhibiting Cancer Cell Glycolysis. Co-author DOI 10.1158/1078-0432.ccr-18-2297↗
  26. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy. Co-author DOI 10.21037/cco.2019.03.02↗
  27. Aberrant upregulation of KLK10 promotes metastasis via enhancement of EMT and FAK/SRC/ERK axis in PDAC. Co-author DOI 10.1016/j.bbrc.2018.03.194↗
  28. Integrated expression profiling of potassium channels identifys KCNN4 as a prognostic biomarker of pancreatic cancer. Co-author DOI 10.1016/j.bbrc.2017.10.072↗

Closest collaborators

The 25 strongest of 70 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shu‐Heng Jiang · 23 shared papers, 2017–2026 · strength 3.24
  2. Zhigang Zhang · 20 shared papers, 2017–2026 · strength 2.50
  3. Yongwei Sun · 16 shared papers, 2017–2024 · strength 1.96
  4. Qing Li · 13 shared papers, 2018–2025 · strength 1.62
  5. Xueli Zhang · 10 shared papers, 2019–2026 · strength 1.43
  6. Xiaomei Yang · 7 shared papers, 2019–2026 · strength 1.14
  7. Hong‐Fei Yao · 6 shared papers, 2022–2026 · strength 1.07
  8. Yan‐Miao Huo · 7 shared papers, 2020–2026 · strength 1.05
  9. Linli Yao · 7 shared papers, 2021–2026 · strength 1.02
  10. Minwei Yang · 8 shared papers, 2018–2024 · strength 1.02
  11. Lili Zhu · 6 shared papers, 2018–2024 · strength 0.82
  12. Qin Yang · 7 shared papers, 2019–2023 · strength 0.70
  13. Xu Wang · 6 shared papers, 2019–2023 · strength 0.67
  14. Dejun Liu · 4 shared papers, 2022–2026 · strength 0.67
  15. Jia-Hao Zheng · 4 shared papers, 2022–2024 · strength 0.63
  16. Rongkun Li · 5 shared papers, 2019–2023 · strength 0.60
  17. Yu-Heng Zhu · 3 shared papers, 2024–2026 · strength 0.58
  18. Dejun Liu · 5 shared papers, 2020–2022 · strength 0.58
  19. Xin Xing · 4 shared papers, 2017–2025 · strength 0.51
  20. Dongxue Li · 3 shared papers, 2022–2025 · strength 0.47
  21. Jian‐Yu Yang · 5 shared papers, 2017–2022 · strength 0.45
  22. Dong‐Xue Li · 2 shared papers, 2025 · strength 0.43
  23. Aziguli Tulamaiti · 2 shared papers, 2025 · strength 0.43
  24. Xia-Qing Li · 2 shared papers, 2025 · strength 0.43
  25. Luju Jiang · 2 shared papers, 2025–2026 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.